Phase 1b Study of Weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma

Phase 1 Completed 107 enrolled Amgen

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of the study is to assess the safety, tolerability and activity of a once-weekly regimen of carfilzomib in combination with lenalidomide and dexamethasone for the treatment of multiple myeloma.

Timeline

Start: 2015-04-30
Primary completion: 2019-10-28
Completion: 2019-10-28

Publications

Background Biran N, Siegel D, Berdeja JG, Raje N, Cornell RF, Alsina M, Kovacsovics T, Fang B, Kimball AS, Landgren O. Weekly carfilzomib, lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: A phase 1b study. Am J Hematol. 2019 Jul;94(7):794-802. doi: 10.1002/ajh.25498. Epub 2019 May 13.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Carfilzomib	Other / unclassified	56 mg/m2	Intravenous
Subject	Carfilzomib	Other / unclassified	70 mg/m2	Intravenous
Background	Dexamethasone	Small molecule	40 mg	Oral
Background	Lenalidomide	Other / unclassified	25 mg	Oral

Phase 1b Study of Weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma

Summary

Timeline

Publications

Drugs

Indications